Bio-Thera Solutions Reports an Initiation of P-III Clinical Trial of BAT2306, a Proposed Biosimilar of Cosentyx (secukinumab) for Plaque Psoriasis
Shots:
- The company initiated the P-III clinical study evaluating the efficacy and safety of BAT2306 vs Cosentyx in patients with mod. to sev. PsO
- Secukinumab is a human IgG1κ mAb that binds to the protein interleukin (IL)-17A. The company intends to submit the BLA/MAA to the NMPA, US FDA, EMA, and other regulatory bodies with the request for approval for all of the available indications
- The company is currently developing multiple additional biosimilar products for the global market incl. biosimilar versions of Actemra, Simponi, Stelara, and Nucala. Additionally, Qletli (biosimilar, adalimumab) and Pobevcy (biosimilar, bevacizumab) have been approved in China
Ref: Businesswire | Image: Bio-Thera Solutions
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
